Anteris Technologies announces 100 patients treated with DurAVR THV

Anteris Technologies (AVR) Global announces a significant milestone in our mission to restore heart valve patients to healthy function. Our first in class, biomimetic DurAVR Transcatheter Heart Valve, THV, has now been used to treat over 100 patients worldwide, marking a major achievement in our goal to revolutionize cardiac care in patients affected by severe aortic stenosis. Anteris Chief Medical Officer, Chris Meduri, M.D., commented: “We are incredibly proud to have reached this milestone, which represents years of dedication, research, and importantly collaboration with expert physicians in the field. The excellent hemodynamic performance we are seeing is noteworthy in that it shows that DurAVR has the potential to restore natural heart valve function and thereby redefine what success looks like in the treatment of aortic stenosis.”